Tests GFH276 with cetuximab or chemotherapy in advanced cancers with RAS mutation
Tests GFH276 with other drugs in adults with RAS-mutated cancers.
Plain-language title generated from the registry record
Registry title: A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Key facts
- Where
- Clayton, Concord, Epping, Frankston, North Ryde, and Woodville South, AustraliaSee the 6 sites
- Phase
- Phase 1/2
Where in Australia
- Monash Health (Monash Medical Centre)Clayton, AustraliaTaking people
- Concord Cancer Centre, Concord Repatriation General Hospital, Sydney Local Health DistrictConcord, AustraliaNot yet recruiting
- Northern HealthEpping, AustraliaNot yet recruiting
- PASO MedicalFrankston, AustraliaTaking people
- Macquarie University / Clinical Trials UnitNorth Ryde, AustraliaTaking people
- The Queen Elizabeth HospitalWoodville South, AustraliaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Genfleet Therapeutics (Shanghai) Inc.
- Trial code
- NCT07678593
- Record updated
- 5 October 2026
- Original description
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS MutationRead full original descriptionShow less
A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Inclusion: Age ≥ 18 years; Histologically or cytologically confirmed locally advanced or metastatic solid tumor and PDAC with RAS mutation or KRAS amplification; At least one measurable lesion according to RECIST v1.1; ECOG performance status 0 or 1; Life expectancy > 3 months; Adequate organ function; Willing to provide written informed consent; Fertile participants must use effective contraception.
Exclusion: For participants with known concomitant second oncodriver for PDAC or for solid tumors; Prior anticancer therapy within 28 days or 5 half-lives; Other active malignancy within 3 years; Symptomatic brain metastases, leptomeningeal disease, spinal cord compression, or primary brain tumor; History of active clinically significant cardiovascular dysfunction; With active infection (HIV, HBV, HCV, syphilis); Diagnosis of deep vein thrombosis or pulmonary embolism within 3 months; Hypersensitivity to study drugs, or inability to swallow tablets or comply with study procedures; History of central nervous system (CNS)disease; Presence of clinically significant interstitial lung disease, radiation pneumonitis, or immune-related pneumonia that requires treatment; The presence of clinical or radiological evidence of intestinal obstruction; With uncontrollable or symptomatic pleural effusion, ascites, or pericardial effusion.